Paper Details

  1. Home
  2. Paper Details

Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.

Author: ArmstrongApril W, MaChelsea

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Ipilimumab was associated with immune-mediated diarrhea and colitis (0.0017 cases per 100 person-years), vemurafenib with keratoacanthomas and squamous cell carcinoma (0.0025 cases per 100 person-years), interferon alfa-2b with depression (0.0002 cases per 100 person-years), dacarbazine with respiratory toxicity and dyspnea (0.0001 and 0.00008 cases per 100 person-years, respectively), and interleukin-2 with vascular leak syndrome (0.17 and 0.15 cases per 100 person-years, respectively).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Current immunomodulatory agents for stage III and IV melanoma exert different mechanisms of action that manifest in distinct adverse events. OBJECTIVE: This systematic review aims to synthesize safety data from clinical trials on ipilimumab, vemurafenib, interferon (IFN) alfa-2b, dacarb...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/09546634.2013.813897

データ提供：米国国立医学図書館（NLM）

Uncovering the Landscape of Severe Adverse Events in Advanced Melanoma Treatment

Advanced melanoma presents a significant challenge for oncologists, and current immunomodulatory agents often come with a spectrum of severe adverse events. This [systematic review] synthesizes safety data from clinical trials on five melanoma therapies: ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine, and interleukin-2. The authors aim to provide a comprehensive overview of the severe adverse events associated with each therapy, informing clinical decision-making and risk assessment.

A Comprehensive Map of Severe Adverse Events in Melanoma Treatment

This review provides a valuable resource for clinicians managing advanced melanoma, offering a comprehensive overview of the severe adverse events associated with different treatment options. By carefully analyzing data from clinical trials, the authors have created a map of the potential risks associated with each therapy, informing the selection of the most appropriate treatment approach for each individual patient.

Informed Decision-Making: A Crucial Step in Melanoma Management

This review underscores the importance of [informed decision-making] in managing advanced melanoma. By understanding the potential risks and benefits of different treatment options, clinicians can engage in thoughtful discussions with their patients to develop personalized treatment plans that balance efficacy with safety. This approach is crucial for ensuring the best possible outcomes for patients with advanced melanoma.

Dr. Camel's Conclusion

This review is like a compass guiding us through the vast and often treacherous desert of advanced melanoma treatment. The detailed analysis of severe adverse events associated with different therapies is essential for navigating the complex decisions faced by clinicians and patients. By carefully weighing the risks and benefits of each treatment option, we can strive to achieve the best possible outcomes for patients with this challenging disease.
Date :
  1. Date Completed 2014-04-14
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

23763243

DOI: Digital Object Identifier

10.3109/09546634.2013.813897

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.